Trials / Terminated
TerminatedNCT00926107
Study of the mTOR Inhibitor Temsirolimus (CCI-779) to Treat Ovarian Cancer With CA125 Only Relapse
Study of the mTOR Inhibitor Temsirolimus(CCI-779) in Patients With CA125 Only Relapse of Ovarian Cancer. A Phase II Study by the Hellenic Cooperative Oncology Group.
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- Hellenic Cooperative Oncology Group · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to determine the efficacy of Temsirolimus in patients with ovarian cancer with CA125 only relapse after first-line platinum-based chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Temsirolimus | Temsirolimus 25mg weekly until clinical progression |
Timeline
- Start date
- 2009-06-01
- Primary completion
- 2011-10-01
- Completion
- 2011-10-01
- First posted
- 2009-06-23
- Last updated
- 2011-11-10
Locations
12 sites across 1 country: Greece
Source: ClinicalTrials.gov record NCT00926107. Inclusion in this directory is not an endorsement.